CJC-1295 DAC: A Research Overview

What is CJC-1295 DAC?

CJC-1295 DAC is a synthetic peptide analogue developed for laboratory research involving growth hormone–releasing hormone (GHRH) signalling. The addition of a Drug Affinity Complex (DAC) is designed to extend the peptide’s stability and duration of activity in experimental systems.

It is studied primarily for its interaction with GHRH receptors and the downstream signalling pathways associated with growth hormone regulation.

Why is CJC-1295 DAC of Research Interest?

CJC-1295 DAC is of research interest because its modified structure allows researchers to investigate prolonged GHRH receptor activation compared with shorter-acting peptide analogues.

Laboratory studies may examine receptor binding, peptide stability, pharmacological characteristics and signalling pathways associated with the growth hormone axis.

Research into CJC-1295 DAC remains investigational.

CJC-1295 DAC in Laboratory Research

Laboratory research involving CJC-1295 DAC requires appropriate handling, storage and analytical documentation.

Relevant considerations can include peptide identity, purity, stability, storage temperature, protection from moisture and light, and batch-specific analytical documentation where available.

Lyophilised material should be handled according to the relevant laboratory protocol and supporting product documentation.

Research Status

CJC-1295 DAC is an investigational research peptide. It is not supplied by Abyss Biotech as a medicine, treatment or therapeutic product.

Products supplied by Abyss Biotech are intended strictly for laboratory research and analytical purposes.

Important Research Notice

CJC-1295 DAC supplied by Abyss Biotech is for laboratory research use only. It is not intended for human consumption, self-administration, veterinary use, diagnosis or therapeutic use.